A study in people with type 2 diabetes.
- Who can join
- Adults 18 to 70, have obesity, BMI 27+.
- What you take
- Check ClinicalTrials.gov for this trial's study groups and what each group receives.
- How long it lasts
- The full study runs about 2 years.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Obesity. Also studied in: Type 2 Diabetes.
Full scientific study title: Ability of Almonds to Improve Nutrition During GLP-1 Treatment.
Who can join
Adults 18 to 70, have obesity, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Adults aged 18-70 years
- BMI ≥ 27 kg/m2 - 47.5 kg/m2 and diagnosed with type 2 diabetes by their personal physician (e.g., primary care physician, endocrinologist), or BMI ≥ 30 kg/m2 and have obesity and stable access (i.e., at least a two-month supply) to the medication
- Prescribed branded injectable semaglutide or injectable tirzepatide (medication will not be provided as part of the study)
- HbA1c will be measured at Pennington Biomedical at baseline (and follow-up), though the baseline HbA1c levels from Pennington Biomedical will not be used for eligibility criteria
- Use of other medications (diabetes medications or otherwise) are permitted at the discretion of the Medical Investigator
Key exclusion criteria
- Pregnancy or breastfeeding
- Taking or planning to take during the trial a medication, vitamin, or mineral supplement that affects vitamin E levels
- Previous use of a glucagon-like peptide-1 medication in the last 3 months
- Contraindications to glucagon-like peptide-1 medication use or previous adverse reaction/allergy to a glucagon-like peptide-1 receptor agonist medication
- Medical, psychological, cognitive, or other conditions that limit the ability to complete study procedure
Where this trial runs
This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.
Louisiana1 site
- Pennington Biomedical Research CenterBaton Rouge, Louisiana
Timeline
Scheduled start: September 3, 2026. Expected completion: December 1, 2028. Last updated on ClinicalTrials.gov: September 1, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
